Brock Reeve Brock Reeve
Executive Director of the Harvard Stem Cell Institute

Brock Reeve, a graduate of Yale and the Harvard Business School, is Executive Director of the Harvard Stem Cell Institute. In partnership with the Faculty Directors, he has overall responsibility for the operations and strategy of the institute whose mission is to use stem cells, both as tools and as therapies, to understand and treat the root causes of leading degenerative diseases.

HSCI is comprised of the schools of Harvard University and all its affiliated hospitals and research institutions. The institute currently has 60 principal faculty and 70 affiliated faculty.  Under the leadership of the Executive Committee, HSCI invests in scientific research in three main areas – seed grants, core facilities and large-scale disease programs.  Beyond the science, the institute also has programs to address ethics and public policy issues, to provide lab experiences for undergraduates, to educate high school science teachers, science journalists and the public at large.

Brock comes to this role from the commercial sector with extensive experience in both management consulting and operations for technology-based companies, with a focus on life sciences.

Brock’s business career started with the Boston Consulting Group.  Prior to Harvard, Brock was COO and Managing Director of Life Science Insights, an IDC company, a consulting and market research firm specializing in information technology in life sciences.  Previously, Brock was an Associate Partner in the Pharmaceutical and Life Sciences practice in IBM’s Business Consulting Services group, working with biotech and pharmaceutical clients on issues ranging from R&D portfolios to operations strategies.  Brock also has had hands-on operational responsibility in product management and marketing roles in software start-ups as well as additional experience in IT and the healthcare/life science market as the Healthcare Practice Director at Viant Corp. and a Principal at SRI Consulting, where his clients included some of the leading pharmaceutical, biotechnology and medical device companies.